Ewa Haładyj

684 total citations
39 papers, 414 citations indexed

About

Ewa Haładyj is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ewa Haładyj has authored 39 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Rheumatology, 12 papers in Hematology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Ewa Haładyj's work include Systemic Lupus Erythematosus Research (20 papers), Rheumatoid Arthritis Research and Therapies (19 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Ewa Haładyj is often cited by papers focused on Systemic Lupus Erythematosus Research (20 papers), Rheumatoid Arthritis Research and Therapies (19 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Ewa Haładyj collaborates with scholars based in Poland, United States and United Kingdom. Ewa Haładyj's co-authors include Marzena Olesińska, Anna Felis‐Giemza, Agnieszka Paradowska‐Gorycka, Mariusz Sikora, Katarzyna Romanowska‐Próchnicka, Ricard Cervera, Barbara Stypińska, Andrzej Pawlik, Peter C. Taylor and Eugen Feist and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and Annals of the Rheumatic Diseases.

In The Last Decade

Ewa Haładyj

37 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ewa Haładyj Poland 13 224 105 68 61 55 39 414
Sahar M. Abdel Galil Egypt 11 217 1.0× 150 1.4× 106 1.6× 41 0.7× 60 1.1× 17 406
Takaharu Ikeda Japan 13 315 1.4× 155 1.5× 45 0.7× 24 0.4× 34 0.6× 51 500
Jumpei Temmoku Japan 13 197 0.9× 222 2.1× 133 2.0× 43 0.7× 70 1.3× 67 453
Alexandra Audemard‐Verger France 11 168 0.8× 93 0.9× 53 0.8× 73 1.2× 33 0.6× 33 442
Viviana Antonella Pacucci Italy 9 302 1.3× 208 2.0× 71 1.0× 31 0.5× 35 0.6× 17 466
Norifumi Sawamukai Japan 14 359 1.6× 267 2.5× 103 1.5× 134 2.2× 72 1.3× 25 672
Taichiro Miyashita Japan 12 163 0.7× 172 1.6× 141 2.1× 38 0.6× 40 0.7× 24 440
Regina Kurrasch United States 12 266 1.2× 188 1.8× 59 0.9× 71 1.2× 57 1.0× 21 534
Yuxing Shan China 9 198 0.9× 246 2.3× 93 1.4× 53 0.9× 86 1.6× 11 478
Ümit Ölmez Türkiye 13 181 0.8× 132 1.3× 117 1.7× 48 0.8× 35 0.6× 23 478

Countries citing papers authored by Ewa Haładyj

Since Specialization
Citations

This map shows the geographic impact of Ewa Haładyj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ewa Haładyj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ewa Haładyj more than expected).

Fields of papers citing papers by Ewa Haładyj

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ewa Haładyj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ewa Haładyj. The network helps show where Ewa Haładyj may publish in the future.

Co-authorship network of co-authors of Ewa Haładyj

This figure shows the co-authorship network connecting the top 25 collaborators of Ewa Haładyj. A scholar is included among the top collaborators of Ewa Haładyj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ewa Haładyj. Ewa Haładyj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Edwards, Christopher, Gerhard Krönke, Jérôme Avouac, et al.. (2025). Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. The Journal of Rheumatology. 52(4). jrheum.2024–906. 1 indexed citations
2.
Taylor, Peter C., Ewa Haładyj, Inmaculada de la Torre, et al.. (2024). Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study. Rheumatology and Therapy. 12(1). 109–122. 1 indexed citations
3.
4.
Taylor, Peter C., Daniel Aletaha, Raimón Sanmartí, et al.. (2024). Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Lara D. Veeken. 63(10). 2799–2809. 4 indexed citations
5.
Littlejohn, Geoffrey, Tamás Treuer, Kathryn Gibson, et al.. (2023). Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset. Clinical and Experimental Rheumatology. 42(9). 1763–1772. 2 indexed citations
6.
Littlejohn, Geoffrey, Tamás Treuer, Kathryn Gibson, et al.. (2023). Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set. ACR Open Rheumatology. 5(7). 345–353. 2 indexed citations
7.
Hernández‐Cruz, Blanca, Uta Kiltz, Jérôme Avouac, et al.. (2023). Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis. Rheumatology and Therapy. 10(6). 1417–1457. 13 indexed citations
8.
9.
Taylor, Peter C., Cedric Laedermann, Rieke Alten, et al.. (2023). A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. Journal of Clinical Medicine. 12(13). 4527–4527. 22 indexed citations
10.
López‐Romero, Pedro, Inmaculada de la Torre, Ewa Haładyj, Daniel Aletaha, & Josef S Smolen. (2022). Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 81(5). 622–631. 12 indexed citations
11.
Dörner, Thomas, Edward M Vital, Sarah Ohrndorf, et al.. (2022). A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Rheumatology and Therapy. 9(3). 781–802. 16 indexed citations
12.
Bieber, Thomas, Eugen Feist, Alan D. Irvine, et al.. (2022). A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Advances in Therapy. 39(11). 4910–4960. 42 indexed citations
13.
Sowińska, Anna, Barbara Stypińska, Anna Felis‐Giemza, et al.. (2022). IL-1β, IL-10 and TNF-α polymorphisms may affect systemic lupus erythematosus risk and phenotype.. PubMed. 40(9). 1708–1717. 9 indexed citations
14.
Felis‐Giemza, Anna, et al.. (2021). Relationship between type of skin lesions and nailfold capillaroscopy pattern in mixed connective tissue disease. Clinical Rheumatology. 41(1). 281–288. 2 indexed citations
15.
Paradowska‐Gorycka, Agnieszka, Barbara Stypińska, Andrzej Pawlik, et al.. (2018). HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case–control study. Inflammation Research. 67(5). 423–433. 8 indexed citations
16.
Haładyj, Ewa, Mariusz Sikora, Anna Felis‐Giemza, & Marzena Olesińska. (2018). Antimalarials – are they effective and safe in rheumatic diseases?. Reumatologia/Rheumatology. 56(3). 164–173. 58 indexed citations
17.
Haładyj, Ewa & Ricard Cervera. (2016). Do we still need renal biopsy in lupus nephritis?. Reumatologia/Rheumatology. 54(2). 61–66. 24 indexed citations
18.
Haładyj, Ewa & Marzena Olesińska. (2016). Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia/Rheumatology. 54(3). 146–149. 25 indexed citations
19.
Paradowska‐Gorycka, Agnieszka, Andrzej Pawlik, Katarzyna Romanowska‐Próchnicka, et al.. (2016). Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis. PLoS ONE. 11(8). e0160769–e0160769. 35 indexed citations
20.
Felis‐Giemza, Anna, et al.. (2014). Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatology International. 35(3). 385–392. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sahar M. Abdel Galil Breakdown of academic impact, for papers by Takaharu Ikeda Breakdown of academic impact, for papers by Jumpei Temmoku Breakdown of academic impact, for papers by Alexandra Audemard‐Verger Breakdown of academic impact, for papers by Viviana Antonella Pacucci Breakdown of academic impact, for papers by Norifumi Sawamukai Breakdown of academic impact, for papers by Taichiro Miyashita Breakdown of academic impact, for papers by Regina Kurrasch Breakdown of academic impact, for papers by Yuxing Shan Breakdown of academic impact, for papers by Ümit Ölmez
Rankless by CCL
2026